Previous 10 | Next 10 |
2024-05-17 05:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-14 10:22:08 ET More on Palisade Bio Palisade Bio stock rallies 50% premarket on colitis drug update Palisade Bio stock rallies nearly 100% on colitis drug analysis Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisa...
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory milestones into 2025 ...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisadeȁ...
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its ...
2024-05-02 08:42:31 ET More on Palisade Bio Palisade Bio stock rallies 50% premarket on colitis drug update Palisade Bio stock rallies nearly 100% on colitis drug analysis Read the full article on Seeking Alpha For further details see: Palisade Bio looks ...
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered int...
2024-05-01 10:41:49 ET DENVER, Colo., May 01, 2024 ( 247marketnews.com )- Brera Holdings (NASDAQ: BREA ), Palisade Bio, Inc. (Nasdaq: PALI ), Getaround (NYSE: GETR ), CytomX Therapeutics, Inc. (Nasdaq: CTMX ), and Predictive Oncology Inc...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 52.9% to $0.1422 on volume of 108,274,564 shares CytomX Therapeutics Inc. (CTMX) rose 71.8% to $2.8 on volume of 31,588,176 shares Getaround Inc. (GETR) rose 35.9% to $0.2754 on volume of 26,693,135 shares P...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...